DoD awards $8.2B for 100M mRNA vaccine doses to ModernaTX, Inc

Contract Overview

Contract Amount: $8,204,906,278 ($8.2B)

Contractor: Modernatx, Inc.

Awarding Agency: Department of Defense

Start Date: 2020-08-11

End Date: 2023-08-10

Contract Duration: 1,094 days

Daily Burn Rate: $7.5M/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: 100M SARS-COV-2 MRNA-1273 VACCINE DOSES

Place of Performance

Location: CAMBRIDGE, MIDDLESEX County, MASSACHUSETTS, 02139

State: Massachusetts Government Spending

Plain-Language Summary

Department of Defense obligated $8.20 billion to MODERNATX, INC. for work described as: 100M SARS-COV-2 MRNA-1273 VACCINE DOSES Key points: 1. Significant investment in vaccine production capacity. 2. Sole-source award raises questions about price discovery and potential savings. 3. Contract duration of nearly three years suggests long-term supply needs. 4. High value contract indicates critical national health security objective. 5. Focus on pharmaceutical manufacturing highlights a key industrial capability.

Value Assessment

Rating: questionable

The contract value of over $8.2 billion for 100 million doses equates to approximately $82 per dose. Without competitive bidding, it is difficult to benchmark this price against market alternatives or assess if it represents optimal value for taxpayer funds. Similar large-scale vaccine procurements by other government agencies or international bodies could offer comparative data, but the sole-source nature of this award limits direct comparison and suggests potential for higher unit costs than might be achieved through competition.

Cost Per Unit: Approximately $82 per dose. Benchmarking is difficult due to sole-source award.

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning only one bidder, ModernaTX, Inc., was solicited. This approach is typically used when only one responsible source is available or when there is a compelling urgency. The lack of competition means that the government did not benefit from a bidding process that could have driven down prices through market forces. This limits the government's ability to explore alternative suppliers or negotiate more favorable terms.

Taxpayer Impact: The sole-source nature of this award means taxpayers may have paid a premium, as competitive pressures that typically lead to cost savings were absent.

Public Impact

Beneficiaries include the U.S. military personnel and their families, as well as potentially broader public health initiatives. Services delivered include the manufacturing and supply of critical mRNA vaccine doses. Geographic impact is national, ensuring supply chain resilience for a vital medical countermeasure. Workforce implications include support for advanced pharmaceutical manufacturing jobs.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source award limits price competition and potential savings.
High unit cost per dose warrants further justification and benchmarking.
Contract duration and value could indicate potential for cost overruns if not managed closely.

Positive Signals

Ensures critical supply of a vital public health asset.
Supports domestic pharmaceutical manufacturing capabilities.
Long-term contract provides supply chain stability.

Sector Analysis

The pharmaceutical manufacturing sector is characterized by high R&D costs, stringent regulatory requirements, and significant economies of scale. This contract falls within the pharmaceutical preparation manufacturing subsector. The global vaccine market is substantial, with governments often acting as major purchasers to ensure national health security. Comparable spending benchmarks for large-scale vaccine procurements are often driven by specific public health emergencies and can vary widely based on the disease, technology, and scale.

Small Business Impact

This contract does not appear to have a small business set-aside. Given the scale and nature of the award to a large pharmaceutical company, subcontracting opportunities for small businesses may exist within the supply chain for raw materials, logistics, or ancillary services, but direct set-aside provisions are not indicated.

Oversight & Accountability

Oversight for this contract would typically fall under the Department of Defense's contracting and financial management oversight mechanisms. Accountability measures would include performance monitoring against delivery schedules and quality standards. Transparency is facilitated through contract databases like FPDS, though the sole-source nature limits detailed public insight into the negotiation process. Inspector General jurisdiction would apply to any allegations of fraud, waste, or abuse.

Related Government Programs

COVID-19 Vaccine Procurement
Biopharmaceutical Manufacturing Contracts
Department of Defense Medical Supplies
National Stockpile Additions

Risk Flags

Sole-source award
High unit cost
Lack of competitive benchmarking

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $8.20 billion to MODERNATX, INC.. 100M SARS-COV-2 MRNA-1273 VACCINE DOSES

Who is the contractor on this award?

The obligated recipient is MODERNATX, INC..

Which agency awarded this contract?

Awarding agency: Department of Defense (Department of the Army).

What is the total obligated amount?

The obligated amount is $8.20 billion.

What is the period of performance?

Start: 2020-08-11. End: 2023-08-10.

What is the track record of ModernaTX, Inc. in fulfilling large-scale government contracts, particularly for vaccine production?

ModernaTX, Inc. has a relatively recent but significant track record in large-scale government contracts, primarily driven by the COVID-19 pandemic. Their mRNA-1273 vaccine received Emergency Use Authorization from the FDA, leading to substantial contracts with the U.S. government, including Operation Warp Speed initiatives managed by agencies like the Department of Health and Human Services (HHS) and the Department of Defense (DoD). These contracts involved the manufacturing and delivery of hundreds of millions of vaccine doses. While the company successfully scaled production rapidly to meet unprecedented demand, the specifics of past performance, including on-time delivery rates, quality control adherence, and any challenges encountered, would be detailed in internal government performance reports and contract close-out documents. The scale of this current $8.2 billion award suggests a continued reliance on Moderna's production capacity, implying a satisfactory, albeit potentially costly, performance history in prior engagements.

How does the per-unit cost of $82 compare to other government vaccine procurements or commercial market rates?

The per-unit cost of approximately $82 for the Moderna mRNA vaccine is on the higher end when compared to historical government vaccine procurements for routine immunizations, which often cost significantly less per dose. However, direct comparisons are challenging due to several factors. This contract was awarded during a period of high global demand and supply chain constraints for COVID-19 vaccines. Furthermore, the sole-source nature of this award means it was not subjected to competitive bidding, which typically drives down prices. Commercial market rates for COVID-19 vaccines have also varied, with initial prices reflecting the urgency and R&D investment. While some government contracts for COVID-19 vaccines secured lower prices through bulk purchasing and negotiation, the $82 figure suggests that this specific award may not represent the most cost-effective procurement, potentially due to the lack of competition and the specific terms negotiated.

What are the primary risks associated with a sole-source award of this magnitude for vaccine supply?

The primary risks associated with a sole-source award of this magnitude for vaccine supply include lack of price competition, potential for inflated costs, and reduced incentive for the contractor to optimize efficiency or offer innovative solutions. Without competing bids, the government relinquishes the opportunity to leverage market forces to secure the best possible price. This can lead to taxpayers bearing a higher cost than might be achieved through a competitive process. Additionally, reliance on a single supplier creates supply chain vulnerability; any disruption in the contractor's operations could have significant consequences for national vaccine availability. While sole-source awards are sometimes justified by urgency or unique capabilities, they necessitate robust oversight to ensure fair pricing and performance standards are met to mitigate these inherent risks.

What is the expected impact of this contract on the U.S. pharmaceutical manufacturing sector and national health security?

This contract is expected to have a significant positive impact on both the U.S. pharmaceutical manufacturing sector and national health security. By securing a large quantity of mRNA vaccine doses from ModernaTX, Inc., the Department of Defense is bolstering the nation's capacity to respond to health threats, whether pandemics or other biological agents requiring vaccine countermeasures. This large, long-term commitment provides financial stability and supports continued investment in advanced manufacturing technologies and skilled labor within the U.S. pharmaceutical industry. It reinforces domestic production capabilities, reducing reliance on foreign sources and enhancing supply chain resilience. This strengthens national health security by ensuring access to critical medical countermeasures and supporting the growth of a vital high-tech industry.

What are the historical spending patterns for pharmaceutical preparation manufacturing by the Department of Defense?

Historical spending patterns for pharmaceutical preparation manufacturing by the Department of Defense (DoD) have generally focused on vaccines, therapeutics, and medical supplies necessary for military personnel and readiness. Prior to the COVID-19 pandemic, annual spending in this category, while substantial, was typically lower and more predictable, often directed towards routine immunizations, treatments for service-connected conditions, and specific operational needs. The pandemic dramatically altered these patterns, leading to unprecedented increases in spending on vaccine development, manufacturing, and procurement across multiple agencies, including the DoD. This $8.2 billion award to ModernaTX, Inc. represents a significant outlier compared to pre-pandemic spending levels for pharmaceutical manufacturing, reflecting the extraordinary circumstances and national priorities during a global health crisis. Analyzing historical data requires segmenting spending before and after major events like the pandemic.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Solicitation ID: W911QY20R0043

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Modernatx Inc.

Address: 200 TECHNOLOGY SQ, CAMBRIDGE, MA, 02139

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $8,204,906,278

Exercised Options: $8,204,906,278

Current Obligation: $8,204,906,278

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: YES

Timeline